Keep up to date on the newest research and clinical application of immunotherapy treatments in colorectal cancer with leading experts Dr Benjamin Schlechter and Marwan Fakih.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986437). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Colorectal Cancer https://www.medscape.com/viewarticle/776784

Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives https://pubmed.ncbi.nlm.nih.gov/30543589/

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/35660797/

Dostarlimab: The Miracle Drug for the Treatment of Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/36060435/

Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers https://pubmed.ncbi.nlm.nih.gov/32251400/

Lynch Syndrome https://www.ncbi.nlm.nih.gov/books/NBK431096/

Optimal Management of Low Anterior Resection Syndrome: Colorectal Cancer (Update) https://pubmed.ncbi.nlm.nih.gov/32730011/

Pembrolizumab (Rx) https://reference.medscape.com/drug/keytruda-pembrolizumab-999962

Carcinomatosis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/carcinomatosis

Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study https://pubmed.ncbi.nlm.nih.gov/32919526/

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/35427471/

Circulating Tumor DNA Test May Help Guide GI Cancer Management https://www.medscape.com/viewarticle/982900

Durvalumab and Tremelimumab Combination Therapy Versus Durvalumab or Tremelimumab Monotherapy for Patients With Solid Tumors: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/32664183/

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial https://pubmed.ncbi.nlm.nih.gov/34970487/

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34196693/

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36892833/

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) https://pubmed.ncbi.nlm.nih.gov/32343640/

Regorafenib Plus Nivolumab in Patients With Mismatch Repair-Proficient/Microsatellite Stable Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicentre Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/37090438/

CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1493

iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics https://pubmed.ncbi.nlm.nih.gov/28271869/

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer https://clinicaltrials.gov/ct2/show/NCT03860272

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer https://clinicaltrials.gov/ct2/show/NCT05608044

When you see an older adult with colorectal cancer, how do you fit your care to their needs? Join Dr Benjamin Schlechter and geriatric medical oncology expert Dr Nadine McCleary for clinical pearls.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988970). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Colorectal Cancer https://www.medscape.com/viewarticle/776784

Comprehensive Geriatric Assessment--A Guide for the Non-specialist https://pubmed.ncbi.nlm.nih.gov/24118661/

Comprehensive Geriatric Assessment for Older Patients With Cancer https://pubmed.ncbi.nlm.nih.gov/17488980/

Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals https://pubmed.ncbi.nlm.nih.gov/31616281/

NCCN Guidelines https://www.nccn.org/guidelines/category_1

ePrognosis https://eprognosis.ucsf.edu/

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/29590544/

Oxaliplatin https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oxaliplatin

Colon Cancer Staging https://emedicine.medscape.com/article/2006674-overview

Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set https://pubmed.ncbi.nlm.nih.gov/18467725/

Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07 https://pubmed.ncbi.nlm.nih.gov/17470851/

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer https://pubmed.ncbi.nlm.nih.gov/15175436/

Colon Cancer Medication https://emedicine.medscape.com/article/277496-medication

Capecitabine https://www.cancer.gov/publications/dictionaries/cancer-drug/def/capecitabine

The ARCAD Advanced Colorectal Cancer Database--Open for Business https://pubmed.ncbi.nlm.nih.gov/22104572/

Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years https://pubmed.ncbi.nlm.nih.gov/22665536/

FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data https://pubmed.ncbi.nlm.nih.gov/30878317/

Alliance for Clinical Trials in Oncology https://www.allianceforclinicaltrialsinoncology.org/main/

Cancer and Aging Research Group https://www.mycarg.org/

Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA Collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/33271092/

Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer? https://ascopubs.org/doi/full/10.1200/JCO.2007.11.6582

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials | JNCI Cancer Spectrum | Oxford Academic (oup.com) https://academic.oup.com/jncics/article/6/2/pkac014/6537541

Join Drs Benjamin Schlechter and Harvey Mamon as they discuss treatment options for patients with stage II and III rectal cancer based on new data from the most recent clinical trial results.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988971). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Colon Cancer https://emedicine.medscape.com/article/277496-overview

Colon Cancer Staging https://emedicine.medscape.com/article/2006674-overview

Signal Transduction https://www.cancer.gov/publications/dictionaries/cancer-terms/def/signal-transduction

Preoperative Treatment of Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/37272534/

Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial https://pubmed.ncbi.nlm.nih.gov/24419115/

FOLFOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen

Cancer Therapy Evaluation Program https://ctep.cancer.gov/

Common Terminology Criteria for Adverse Events (CTCAE) v5.0 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) https://pubmed.ncbi.nlm.nih.gov/37270691/

Abdominoperineal Resection https://www.ncbi.nlm.nih.gov/books/NBK574568/

The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer https://pubmed.ncbi.nlm.nih.gov/32670875/

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy https://pubmed.ncbi.nlm.nih.gov/35483010/

Total Neoadjuvant Therapy (TNT) Versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33987952/

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS) https://classic.clinicaltrials.gov/ct2/show/NCT05610163

Factors Influencing Downstaging After Neoadjuvant Long-Course Chemoradiotherapy in Rectal Carcinoma https://pubmed.ncbi.nlm.nih.gov/35545701/

Carcinoembryonic Antigen https://www.ncbi.nlm.nih.gov/books/NBK578172/

Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33301740/

Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33862000/

FOLFIRINOX Regimen https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfirinox-regimen

Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery - A Five-Year Follow-Up of the RAPIDO Trial https://pubmed.ncbi.nlm.nih.gov/36661037/